Table 1.
Characteristics of the study groups (108 patients).
| Characteristic | HCVAD group (66 patients) No. (%) | CALGB group (42 patients) No. (%) |
|---|---|---|
|
| ||
| Median age (range) | 32.5(19–73) | 34(18–69) |
|
| ||
| Gender: | ||
| Male | 42 (64) | 26 (62) |
| Female | 24 (36) | 16 (38) |
|
| ||
| Splenomegaly | 17 (26) | 12 (28) |
|
| ||
| Hepatomegaly | 8 (12) | 5 (12) |
|
| ||
| Lymphadenopathy | 26 (40) | 15 (36) |
|
| ||
| CNS disease at diagnosis | 6 (9) | 5 (12) |
|
| ||
| Mediastinal mass | 6(9) | 3 (7) |
|
| ||
| WBC count (cell/ml): | ||
| < 30,000 | 48 (73) | 33 (79) |
| 30,000–100,000 | 12 (18) | 6 (14) |
| >100,000 | 6 (9) | 3 (7) |
|
| ||
| Platelet count <100,000/ml | 45 (68) | 30 (71) |
|
| ||
| Hemoglobin level < 10 g/dL | 48 (73) | 32 (76) |
|
| ||
| LDH > 600 (U/L) | 28 (55)* | 11 (52)** |
|
| ||
| Immunophenotype: | ||
| CD10 negative Pre-B | 12 (18) | 6 (14) |
| CD10 positive common ALL | 46 (70) | 28 (67) |
| T-cell ALL | 8 (12) | 8 (19) |
|
| ||
| Myeloid markers: | ||
| Positive | 11 (30) | 7 (27) |
| Negative | 26 (70) | 19 (73) |
| Not done/unknown | 29 | 16 |
|
| ||
| Karyotype: (%, percentage of assessable patients) | ||
| Normal | 27 (52) | 17 (55) |
| Ph-positive (by FISH) | 8 (16) | 5 (17) |
| t(1,19) | 0 (0) | 1 (3) |
| t(4,11) | 1 (2) | 1 (3) |
| t(12,21) | 7 (13) | 4 (13) |
| Isolated +8, or −6q | 3 (6) | 1 (3) |
| Hyperdiploid | 2 (4) | 1 (3) |
| Hypodiploid | 1 (2) | 0 (0) |
| Insufficient/not done | 17 | 12 |
Abbreviation: CNS, central nervous system; WBC, white blood cell; LDH, lactic dehydrogenase; Ph, Philadelphia chromosome; FISH, fluorescent in situ hybridization.
*
15 unknown,
**
21 unknown.